Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu

Single-chain Fv (scFv) molecules exhibit highly specific tumour-targeting properties in tumour-bearing mice. However, because of their smaller size and monovalent binding, the quantities of radiolabelled scFv retained in tumours limit their therapeutic applications. Diabodies are dimeric antibody-based molecules composed of two non-covalently associated scFv that bind to antigen in a divalent manner. In vitro, diabodies produced from the anti-HER2/neu (c-erbB-2) scFv C6.5 displayed approximately 40-fold greater affinity for HER2/neu by surface plasmon resonance biosensor measurements and significantly prolonged association with antigen on the surface of SK-OV-3 cells (t1/2 cell surface retention of > 5 h vs 5 min) compared with C6.5 scFv. In SK-OV-3 tumour-bearing scid mice, radioiodinated C6.5 diabody displayed a highly favourable balance of quantitative tumour retention and specificity. By as early as 4 h after i.v. administration, significantly more diabody was retained in tumour (10 %ID g(-1)) than in blood (6.7 %ID ml(-1)) or normal tissue (liver, 2.8 %ID g(-1); lung, 7.1 %ID g(-1); kidney, 5.2 %ID g(-1)). Over the next 20 h, the quantity present in blood and most tissues dropped approximately tenfold, while the tumour retained 6.5 %ID g(-1) or about two-thirds of its 4-h value. In contrast, the 24-h tumour retention of radioiodinated C6.5 scFv monomer was only 1 %ID g(-1). When diabody retentions were examined over the course of a 72-h study and cumulative area under the curve (AUC) values were determined, the resulting tumor-organ AUC ratios were found to be superior to those previously reported for other monovalent or divalent scFv molecules. In conclusion, the diabody format provides the C6.5 molecule with a distinct in vitro and in vivo targeting advantage and has promise as a delivery vehicle for therapeutic agents.

Abstract licence: CC BY

1. 1.

   Adams G. P., McCartney J. E., Tai M. S., Oppermann H., Huston J. S., Stafford W. F., Bookman M. A., Fand I., Houston L. L., Weiner L. M. Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erbB-2 single-chain Fv. Cancer Res. 1993;53(17):4026-4034.

   Not in our library

2. 2.

   Allred D. C., Clark G. M., Molina R., Tandon A. K., Schnitt S. J., Gilchrist K. W., Osborne C. K., Tormey D. C., McGuire W. L. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol. 1992;23(9):974-979.

   Not in our library10.1016/0046-8177(92)90257-4 (opens in a new tab)

3. 3.

   Beaumier P. L., Krohn K. A., Carrasquillo J. A., Eary J., Hellström I., Hellström K. E., Nelp W. B., Larson S. M. Melanoma localization in nude mice with monoclonal Fab against p97. J Nucl Med. 1985;26(10):1172-1179.

   Not in our library

4. 4.

   Begent R. H., Verhaar M. J., Chester K. A., Casey J. L., Green A. J., Napier M. P., Hope-Stone L. D., Cushen N., Keep P. A., Johnson C. J. Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library. Nat Med. 1996;2(9):979-984.

   Not in our library10.1038/nm0996-979 (opens in a new tab)

5. 5.

   Berchuck A., Kamel A., Whitaker R., Kerns B., Olt G., Kinney R., Soper J. T., Dodge R., Clarke-Pearson D. L., Marks P. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res. 1990;50(13):4087-4091.

   Not in our library

6. 6.

   Bird R. E., Hardman K. D., Jacobson J. W., Johnson S., Kaufman B. M., Lee S. M., Lee T., Pope S. H., Riordan G. S., Whitlow M. Single-chain antigen-binding proteins. Science. 1988;242(4877):423-426.

   Not in our library10.1126/science.3140379 (opens in a new tab)

7. 7.

   Breitling F., Dübel S., Seehaus T., Klewinghaus I., Little M. A surface expression vector for antibody screening. Gene. 1991;104(2):147-153.

   Not in our library10.1016/0378-1119(91)90244-6 (opens in a new tab)

8. 8.

   Colcher D., Bird R., Roselli M., Hardman K. D., Johnson S., Pope S., Dodd S. W., Pantoliano M. W., Milenic D. E., Schlom J. In vivo tumor targeting of a recombinant single-chain antigen-binding protein. J Natl Cancer Inst. 1990;82(14):1191-1197.

   Not in our library10.1093/jnci/82.14.1191 (opens in a new tab)

9. 9.

   Earp H. S., Dawson T. L., Li X., Yu H. Heterodimerization and functional interaction between EGF receptor family members: a new signaling paradigm with implications for breast cancer research. Breast Cancer Res Treat. 1995;35(1):115-132.

   Not in our library10.1007/bf00694752 (opens in a new tab)

10. 10.

    Fujimori K., Covell D. G., Fletcher J. E., Weinstein J. N. Modeling analysis of the global and microscopic distribution of immunoglobulin G, F(ab')2, and Fab in tumors. Cancer Res. 1989;49(20):5656-5663.

    Not in our library

11. 11.

    Hancock M. C., Langton B. C., Chan T., Toy P., Monahan J. J., Mischak R. P., Shawver L. K. A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines. Cancer Res. 1991;51(17):4575-4580.

    Not in our library

12. 12.

    Holliger P., Prospero T., Winter G. "Diabodies": small bivalent and bispecific antibody fragments. Proc Natl Acad Sci U S A. 1993;90(14):6444-6448.

    Not in our library10.1073/pnas.90.14.6444 (opens in a new tab)

13. 13.

    Hu S., Shively L., Raubitschek A., Sherman M., Williams L. E., Wong J. Y., Shively J. E., Wu A. M. Minibody: A novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts. Cancer Res. 1996;56(13):3055-3061.

    Not in our library

14. 14.

    Huston J. S., George A. J., Adams G. P., Stafford W. F., Jamar F., Tai M. S., McCartney J. E., Oppermann H., Heelan B. T., Peters A. M. Single-chain Fv radioimmunotargeting. Q J Nucl Med. 1996;40(3):320-333.

    Not in our library

15. 15.

    Huston J. S., Levinson D., Mudgett-Hunter M., Tai M. S., Novotný J., Margolies M. N., Ridge R. J., Bruccoleri R. E., Haber E., Crea R. Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc Natl Acad Sci U S A. 1988;85(16):5879-5883.

    Not in our library10.1073/pnas.85.16.5879 (opens in a new tab)

16. 16.

    Jain R. K. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res. 1990;50(3 Suppl):814s-819s.

    Not in our library

17. 17.

    Juweid M., Neumann R., Paik C., Perez-Bacete M. J., Sato J., van Osdol W., Weinstein J. N. Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier. Cancer Res. 1992;52(19):5144-5153.

    Not in our library

18. 18.

    Jönsson U., Fägerstam L., Ivarsson B., Johnsson B., Karlsson R., Lundh K., Löfås S., Persson B., Roos H., Rönnberg I. Real-time biospecific interaction analysis using surface plasmon resonance and a sensor chip technology. Biotechniques. 1991;11(5):620-627.

    Not in our library

19. 19.

    Kaminski M. S., Zasadny K. R., Francis I. R., Milik A. W., Ross C. W., Moon S. D., Crawford S. M., Burgess J. M., Petry N. A., Butchko G. M. Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody. N Engl J Med. 1993;329(7):459-465.

    Not in our library10.1056/nejm199308123290703 (opens in a new tab)

20. 20.

    Karlsson R., Michaelsson A., Mattsson L. Kinetic analysis of monoclonal antibody-antigen interactions with a new biosensor based analytical system. J Immunol Methods. 1991;145(1-2):229-240.

    Not in our library10.1016/0022-1759(91)90331-9 (opens in a new tab)

21. 21.

    King C. R., Kraus M. H., Aaronson S. A. Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science. 1985;229(4717):974-976.

    Not in our library10.1126/science.2992089 (opens in a new tab)

22. 22.

    Kraus M. H., Popescu N. C., Amsbaugh S. C., King C. R. Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms. EMBO J. 1987;6(3):605-610.

    Not in our library10.1002/j.1460-2075.1987.tb04797.x (opens in a new tab)

23. 23.

    Laub P. B., Gallo J. M. NCOMP--a windows-based computer program for noncompartmental analysis of pharmacokinetic data. J Pharm Sci. 1996;85(4):393-395.

    Not in our library10.1021/js9503744 (opens in a new tab)

24. 24.

    Marks J. D., Hoogenboom H. R., Bonnert T. P., McCafferty J., Griffiths A. D., Winter G. By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J Mol Biol. 1991;222(3):581-597.

    Not in our library10.1016/0022-2836(91)90498-u (opens in a new tab)

25. 25.

    Milenic D. E., Yokota T., Filpula D. R., Finkelman M. A., Dodd S. W., Wood J. F., Whitlow M., Snoy P., Schlom J. Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49. Cancer Res. 1991;51(23 Pt 1):6363-6371.

    Not in our library

26. 26.

    Molthoff C. F., Pinedo H. M., Schlüper H. M., Nijman H. W., Boven E. Comparison of the pharmacokinetics, biodistribution and dosimetry of monoclonal antibodies OC125, OV-TL 3, and 139H2 as IgG and F(ab')2 fragments in experimental ovarian cancer. Br J Cancer. 1992;65(5):677-683.

    Not in our library10.1038/bjc.1992.144 (opens in a new tab)

27. 27.

    Pack P., Kujau M., Schroeckh V., Knüpfer U., Wenderoth R., Riesenberg D., Plückthun A. Improved bivalent miniantibodies, with identical avidity as whole antibodies, produced by high cell density fermentation of Escherichia coli. Biotechnology (N Y). 1993;11(11):1271-1277.

    Not in our library10.1038/nbt1193-1271 (opens in a new tab)

28. 28.

    Pack P., Plückthun A. Miniantibodies: use of amphipathic helices to produce functional, flexibly linked dimeric FV fragments with high avidity in Escherichia coli. Biochemistry. 1992;31(6):1579-1584.

    Not in our library10.1021/bi00121a001 (opens in a new tab)

29. 29.

    Perisic O., Webb P. A., Holliger P., Winter G., Williams R. L. Crystal structure of a diabody, a bivalent antibody fragment. Structure. 1994;2(12):1217-1226.

    Not in our library10.1016/s0969-2126(94)00123-5 (opens in a new tab)

30. 30.

    Press O. W., Eary J. F., Appelbaum F. R., Martin P. J., Badger C. C., Nelp W. B., Glenn S., Butchko G., Fisher D., Porter B. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med. 1993;329(17):1219-1224.

    Not in our library10.1056/nejm199310213291702 (opens in a new tab)

31. 31.

    Schier R., Marks J. D., Wolf E. J., Apell G., Wong C., McCartney J. E., Bookman M. A., Huston J. S., Houston L. L., Weiner L. M. In vitro and in vivo characterization of a human anti-c-erbB-2 single-chain Fv isolated from a filamentous phage antibody library. Immunotechnology. 1995;1(1):73-81.

    Not in our library10.1016/1380-2933(95)00007-0 (opens in a new tab)

32. 32.

    Schier R., McCall A., Adams G. P., Marshall K. W., Merritt H., Yim M., Crawford R. S., Weiner L. M., Marks C., Marks J. D. Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site. J Mol Biol. 1996;263(4):551-567.

    Not in our library10.1006/jmbi.1996.0598 (opens in a new tab)

33. 33.

    Slamon D. J., Clark G. M., Wong S. G., Levin W. J., Ullrich A., McGuire W. L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785):177-182.

    Not in our library10.1126/science.3798106 (opens in a new tab)

34. 34.

    Stein R., Blumenthal R., Sharkey R. M., Goldenberg D. M. Comparative biodistribution and radioimmunotherapy of monoclonal antibody RS7 and its F(ab')2 in nude mice bearing human tumor xenografts. Cancer. 1994;73(3 Suppl):816-823.

    Not in our library10.1002/1097-0142(19940201)73:3+<816::aid-cncr2820731311>3.0.co;2-t (opens in a new tab)

35. 35.

    Wallasch C., Weiss F. U., Niederfellner G., Jallal B., Issing W., Ullrich A. Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3. EMBO J. 1995;14(17):4267-4275.

    Not in our library10.1002/j.1460-2075.1995.tb00101.x (opens in a new tab)

36. 36.

    Ward E. S., Güssow D., Griffiths A. D., Jones P. T., Winter G. Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli. Nature. 1989;341(6242):544-546.

    Not in our library10.1038/341544a0 (opens in a new tab)

37. 37.

    Weiner L. M., Holmes M., Richeson A., Godwin A., Adams G. P., Hsieh-Ma S. T., Ring D. B., Alpaugh R. K. Binding and cytotoxicity characteristics of the bispecific murine monoclonal antibody 2B1. J Immunol. 1993;151(5):2877-2886.

    Not in our library

38. 38.

    Wolff E. A., Schreiber G. J., Cosand W. L., Raff H. V. Monoclonal antibody homodimers: enhanced antitumor activity in nude mice. Cancer Res. 1993;53(11):2560-2565.

    Not in our library

39. 39.

    Yokota J., Yamamoto T., Miyajima N., Toyoshima K., Nomura N., Sakamoto H., Yoshida T., Terada M., Sugimura T. Genetic alterations of the c-erbB-2 oncogene occur frequently in tubular adenocarcinoma of the stomach and are often accompanied by amplification of the v-erbA homologue. Oncogene. 1988;2(3):283-287.

    Not in our library

40. 40.

    Yorke E. D., Beaumier P. L., Wessels B. W., Fritzberg A. R., Morgan A. C. Optimal antibody-radionuclide combinations for clinical radioimmunotherapy: a predictive model based on mouse pharmacokinetics. Int J Rad Appl Instrum B. 1991;18(8):827-835.

    Not in our library10.1016/0883-2897(91)90090-8 (opens in a new tab)

41. 41.

    van de Vijver M., van de Bersselaar R., Devilee P., Cornelisse C., Peterse J., Nusse R. Amplification of the neu (c-erbB-2) oncogene in human mammmary tumors is relatively frequent and is often accompanied by amplification of the linked c-erbA oncogene. Mol Cell Biol. 1987;7(5):2019-2023.

    Not in our library10.1128/mcb.7.5.2019-2023.1987 (opens in a new tab)

• Current status of targeted microbubbles in diagnostic molecular imaging of pancreatic cancer · 2021

  Not checked

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.